Jan 21, 2026
Roche/Genentech announced on June 15–16, 2025 that prasinezumab — an anti-α-synuclein monoclonal antibody — will enter Phase III trials for early Parkinson’s disease after mixed but encouraging Phase II signals.
In this episode (watch on YouTube) we explain the biology behind α-synuclein targeting, summarize...
Jan 7, 2026
In this episode (watch here on YouTube), we dive into one of the most talked-about areas of emerging Parkinson’s research: GLP-1 receptor agonists. Originally developed for diabetes and, more recently, widely used for weight management, GLP-1 medications like semaglutide and liraglutide are now being investigated for...